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Abstract  
Objective: Understanding the fertility of HIV-positive women is critical to estimating HIV 
epidemic trends from surveillance data and planning resource needs and coverage of prevention-
of-mother-to-child transmission services in sub-Saharan Africa. In light of the considerable scale-
up in antiretroviral therapy (ART) coverage over the last decade, we conducted a systematic 
review of the impact of ART on the fertility outcomes of HIV-positive women.  
Methods: We searched Medline, Embase, Popline, PubMed and African Index Medicus. Studies 
were included if they were conducted in sub-Saharan Africa and provided estimates of fertility 
outcomes (live births or pregnancies) among women on ART relative to a comparison group.  
Results: Of 2070 unique references, 18 published papers met all eligibility criteria. Comparisons 
fell into four categories: fertility of HIV-positive women relative to HIV-negative women; 
fertility of HIV-positive women on ART compared to those not yet on ART; fertility differences 
by duration on ART; and temporal trends in fertility among HIV-positive women. Evidence 
indicates that fertility increases after approximately the first year on ART, and that while the 
fertility deficit of HIV-positive women is shrinking, their fertility remains below that of HIV-
negative women. These findings, however, were based on limited data mostly during the period 
2005-2010 when ART scaled-up.  
Conclusions: Existing data are insufficient to characterize how ART has affected the fertility of 
HIV-positive women in sub-Saharan Africa. Improving evidence about fertility among women 
on ART is an urgent priority for planning HIV resource needs and understanding HIV epidemic 
trends. Alternative data sources such as antenatal clinic data, general population cohorts and 
population-based surveys can be harnessed to understand the relationship moving forward. 
 
 
 
keywords HIV, sub-Saharan Africa, antiretroviral therapy, fertility, pregnancy, births, systematic 
review 
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The Impact of ART on the Fertility of HIV-Positive Women in Sub-Saharan Africa: A 
Systematic Review 
 
Introduction 
The fertility of HIV-positive women is a principal determinant of the need for prevention of 
mother-to-child transmission (PMTCT) and paediatric HIV services. Furthermore, 
understanding the relationship between HIV and fertility, and variation in this relationship by 
age, is essential for using HIV prevalence among pregnant women to estimate and track trends in 
the HIV prevalence of the general population over time (1-3). Although much is known about 
the relationship between HIV and fertility in sub-Saharan Africa in the absence of anti-retroviral 
therapy (ART) (3-5), it remains unclear just how the spread of treatment throughout the region 
has affected this important relationship.  
 
Researchers have long recognized the fertility suppressing effect of HIV on fecundity, the 
physiologic ability to have children (3, 6, 7). Because the biological effects of HIV on fecundity 
increase with advancing infection (8), they are most pronounced in older HIV-positive women 
who are likely to have been infected years earlier. There are also behavioural effects of HIV on 
fertility that can be either volitional (i.e., done with an explicit fertility motivation) or non-
volitional. The former include changes in contraceptive use intended to prevent or encourage a 
pregnancy while the latter include changes in divorce, widowhood and remarriage patterns due to 
HIV that indirectly affect fertility.  
 
Before the widespread availability of ART, the fertility of HIV-positive women throughout sub-
Saharan Africa was reduced, compared to similar HIV-negative women, because of a 
combination of biological and behavioural mechanisms. Population-based HIV surveillance 
studies showed there was variation in the so-called ‘fertility discount’ by age, however. At 
younger ages (<20), fertility was higher in HIV-positive women due to selection effects (i.e., 
selection into sexual activity among HIV-positive women). Above age 20, fertility among HIV-
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positive women was reduced by 25-40% compared to HIV-negative women (3, 5). More recently, 
using Demographic and Health Survey (DHS) data from before the widespread availability of 
ART (2003-2006), Chen and Walker (4) showed that the age-specific fertility ratio decreased with 
age until the fertility of HIV-positive women was approximately half that of HIV-negative 
women in the 40-44 age group.  
 
With the growing availability of ART throughout much of sub-Saharan Africa, the relationship 
between HIV and fertility will change (9). Precisely how quickly and to what extent change will 
occur remains unclear because of the recent nature of expanded ART coverage. Given high levels 
of underlying fertility in much of the region, small changes in any factor can carry large 
implications for estimates of PMTCT need and service coverage. Since estimates of paediatric 
HIV infections are derived using models based on the number of HIV-positive pregnant women 
and coverage of PMTCT, this can dramatically affect estimates of children living with HIV. 
Additionally, changes in the fertility discount by age could affect interpretations of prevalence 
trends in antenatal care (ANC) and PMTCT clinic surveillance.  
 
In order to better understand the effect of ART on the fertility of HIV-positive women in sub-
Saharan Africa, we conducted a systematic review of the current literature. We use the term 
fertility in its demographic sense to refer to fertility outcomes: live births and pregnancies. We 
present the results and offer an assessment of the limitations of current data and approaches to 
address this question. We then discuss available data sources and offer suggestions for future 
research to shed light on the relationship between HIV and fertility as it evolves with the 
treatment context.  
 
Methods 
Search strategy 
This systematic review conforms to the PRISMA guidelines (Appendix 1) (10). On 14 October 
2015, Medline, Embase, Popline, and African Index Medicus were searched using combinations 
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of search terms without language or date restrictions. A top-up search for non-Medline records 
was additionally run in PubMed. The review was updated on 26 May 2016. The following 
concepts were included in the search: antiretroviral therapy (including ART, HAART, cART) 
AND fertility outcomes (including pregnancy, birth, reproductive health or fertility). Searching 
for all concepts in subject headings, title and abstract simultaneously proved to have very poor 
specificity. A faceted approach was therefore used, in which the return of each concept in free-
text and subject headings was tested iteratively and the most precise combinations selected for 
inclusion in the final search. In the final search, concepts were combined as follows: 
1. Antiretroviral therapy [subject headings and free-text in title and abstract] 
2. Fertility outcomes [subject headings only] 
3. 1 AND 2 
4. Antiretroviral therapy [subject headings and free-text in title only] 
5. Fertility outcomes [title and abstract free-text] 
6. 4 AND 5 
7. 3 OR 6 
The combination of fertility terms appearing anywhere and ART terms appearing in the abstract 
only was found to have very poor specificity and was therefore removed from the final strategy. 
As the review focus was antiretroviral therapy, terms for HIV infection or seropositivity were not 
included independently. Where possible, animal studies and studies on assisted reproductive 
techniques were excluded. The full search strategy is shown in Appendix 2; there is no formal 
review protocol. Faceted searching was not possible in Popline and African Index Medicus, so a 
simplified version of the strategy was used. The references lists of all retained studies were 
additionally searched by hand.  
 
Eligibility criteria  
Studies were eligible for inclusion if they were conducted in sub-Saharan Africa, contained 
estimates of fertility outcomes (i.e., birth or pregnancy) for HIV-positive women on ART (or 
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during a post-ART time period) over a defined period of time, and permitted a comparison of 
the fertility of HIV-positive women to another population.  
 
Study selection 
Titles and abstracts were screened by one author and full texts were sought for potentially 
relevant publications. In total, 2677 initial references were screened for eligibility and excluded 
for being duplicates (n=607) or through title (n=1647), abstract (n=375) or full-text review 
(n=31). An additional study that met criteria for inclusion was identified by checking the 
references of other reviewed studies (see Fig. 1).  
 
Data extraction and analysis 
Data were extracted on: study setting; time period covered; sample description; design; 
comparisons made; outcome; and key findings. Because fertility is shaped not only by biology, 
but also by behavior and the social and cultural norms of a specific context, the review focused 
on the relative differences in fertility adjusted for age rather than on absolute levels of pregnancy 
rates that may not be generalizable beyond a particular study setting. Substantial heterogeneity in 
comparators, sample inclusion criteria, and control variables prevented the meaningful pooling of 
statistics. 
 
Quality assessment 
In line with the PRISMA guidelines, the risk of bias was assessed, focusing on the comparability 
of comparison populations, selectivity and size of sample, method of measuring pregnancy or 
birth, and appropriate handling of age. Given the strong and non-linear relationship between age 
and fertility, and that women on ART are older on average, it is essential to stratify or use age-
standardized comparison populations to reduce biases introduced by differences in age 
composition. 
 
    ---Figure 1 about here--- 
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Results 
After exclusions, the literature search identified 18 articles that met all study criteria (Table 1). 
Included articles offered at least one of four comparisons: (1) fertility of HIV-positive women on 
ART relative to fertility of HIV-negative women; (2) fertility of HIV-positive women on ART to 
HIV-positive women not yet on ART; (3) fertility of HIV-positive women by time on ART or 
time-varying CD4 count after initiation; or (4) fertility of HIV-positive women before and after 
ART was widely available. Most studies were from a single setting, although five used data from 
multiple countries in the region (11-15). Data came from Uganda (9 studies), South Africa (4), 
Kenya (4), Malawi (2), Rwanda (2), Cote d’Ivoire (2), Zimbabwe (2), Zambia (1), Tanzania (1), 
Gambia (1), Mali (1), Guinea-Bissau (1), Nigeria (1), Burkina Faso (1), Benin (1) and Senegal (1). 
The included countries range widely in HIV prevalence (from 0.5% in Senegal to 18.9% in South 
Africa) (16) and total fertility rate (from 2.4 in South Africa to 6.4 in Mali) (17). 
 
    ---Table 1 about here--- 
 
The majority of studies were conducted in HIV clinics (n=12) or as part of HIV outreach 
programs or studies (n=3). Only three studies used population-based samples: a study that was 
conducted among 12 communities in eastern Zimbabwe (1); one that drew from demographic 
and HIV surveillance sites in Uganda, Tanzania and South Africa (13); and another that used two 
rounds of the nationally-representative Malawi Demographic and Health Survey (DHS) (18). 
These studies were the only to contain data from a more representative sample of HIV-positive 
women, some of whom may not be enrolled in clinical care nor necessarily aware of their HIV 
positive status. Clinic-based studies, however, were better able to accurately assess ART status at 
the time of conception.  
 
Fifteen studies used pregnancy incidence or prevalence as the main outcome. The three 
exceptions were a cross-sectional study from semi-urban Uganda that examined the likelihood of 
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live birth and of pregnancy over the previous three years (19), and two of the population-based 
studies that used age-specific fertility rates and thus focused on live births rather than 
pregnancies (13, 18). Eight of the 16 studies measuring pregnancy used testing or clinical 
examination to determine pregnancy while the others relied on self-reported pregnancy, which 
will be biased toward established pregnancies and pregnancies that end in live birth. On the other 
hand, for estimates of the need for PMTCT and paediatric HIV, live births and more advanced 
pregnancies are the most relevant outcomes. 
 
Studies covered a range of years from 1998-2013 with most person-years of data concentrated in 
the 2005-2010 period, a time in which ART access expanded rapidly in most settings. All studies 
included women from across the reproductive ages, although some (1, 11, 13, 18, 20, 21) handled 
age more thoroughly in analyses than others (see Table 1).  
 
HIV-positive women’s fertility relative to HIV-negative women 
Only three studies (1, 13, 18) had a purposefully-selected HIV-negative comparison group, 
although two more made indirect comparisons to national level data (21, 22). Gregson and 
colleagues (1) found that in a period of increasingly good access to ART in Zimbabwe (2009-
2011), the age-adjusted prevalence of pregnancy among HIV-positive women (not all of whom 
were aware of their status) was 75% that of HIV-negative women. With the exception of the 
youngest age group (15-24) in which fertility did not differ by HIV status, HIV-positive women 
had substantially lower pregnancy prevalence regardless of ART use.  
 
Recently, Marston et al. (13) analysed data from four demographic and HIV surveillance sites in 
Uganda, Tanzania and South Africa. Using data from 59,440 women, the researchers found that 
the gap between the age-specific fertility rates of HIV-positive and HIV-negative women 
narrowed in the post-ART period relative to the years before ART was available. The narrowing 
was principally due to reductions in the fertility of HIV-negative women rather than to increases 
among HIV-positive women whose fertility stayed steady or only slightly increased over the 
 9 
study period (depending on study site). Despite this narrowing, the age-adjusted fertility rate ratio 
of HIV-positive: HIV-negative women still ranged between 0.57 (95% CI 0.64-0.83) to 0.83 
(95% CI 0.78-0.87) across sites and followed the same age-pattern as in the pre-ART period.  
 
The findings from nationally-representative cross-sectional data from Malawi support the 
aforementioned studies (18). Despite a relative increase in the fertility of HIV-positive women 
compared to HIV-negative women between 2004 and 2010, the fertility of HIV-positive women 
remained at least 25% lower than that of HIV negative women in the latter time period (18).  
 
Two of these population-based studies (13, 18) lack data on individual ART use, and therefore 
cannot speak to the relative fertility contribution of women on ART and not on ART, which is 
important for estimating the need for PMTCT and paediatric HIV services. 
 
Fertility of HIV-positive women on ART compared to those not yet on ART 
There was disagreement among studies on the pregnancy incidence of women on ART relative to 
HIV-positive women engaged in care but not yet on ART. Using data from a postpartum sample 
of women attending 11 urban HIV clinics in six sub-Saharan Africa countries, Myer et al. (11) 
compared the pregnancy incidence of women on ART to HIV-positive women in pre-ART care 
after adjusting for a number of variables including age and CD4 count at enrollment. The 
researchers found that pregnancy incidence was 1.74 (95% CI 1.19–2.54) times greater among 
HIV-positive women who recently initiated ART relative to women who had yet to initiate. The 
same trend was noted across study countries although it was stronger in some than in others. 
Similarly, a community-based HIV care program in rural Uganda found that pregnancy incidence 
was twice as high among HIV-positive women on ART (23).  
 
In contrast, a recent study from 26 HIV clinics in Uganda and Kenya found no difference in 
pregnancy incidence comparing women on ART to those not yet on ART. Importantly, these 
researchers adjusted for time-varying clinical stage and CD4 count and robustly accounted for 
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loss-to-follow up and death (14). Another study (24) similarly found no difference in the 
pregnancy incidence of women in an HIV-clinic in Kenya using a nevirapine-based ART regimen 
relative to women not yet on ART after adjusting for sociodemographic characteristics and time-
varying CD4 count. This was similar to the findings of a Kenyan study of HIV-positive women 
in sero-discordant relationships (25). 
 
Two other studies found no difference in pregnancy incidence by ART (26, 27)and another 
found higher pregnancy incidence among women not yet on ART relative to those on ART (15), 
but these studies did not adjust for sociodemographic or health differences among the 
comparison groups.  
 
Fertility differences by duration on ART  
A common approach taken by clinic-based studies was to examine changes in pregnancy 
incidence by time on ART. Some studies prospectively examined women from their initiation on 
ART, while others included women who may have started on ART before study enrollment but 
from whom they had data on time of ART initiation. Most studies found significant variation in 
pregnancy incidence by time on ART. Tweya and colleagues (21), for example, found that 
pregnancy incidence was particularly low among women in an urban Malawian ART clinic during 
their first six months on ART. After those six months, fertility substantially increased among all 
age groups. One study from rural Uganda found that pregnancy incidence peaked 12 to 18 
months after initiation (22), while another study from rural Uganda found peaks at 6 to 12 
months and then again at 4 years presumably due to a birth interval effect (28). In West Africa, 
data from ART clinics in six countries showed pregnancy incidence was highest in year four (12). 
In contrast, a study from Johannesburg, South Africa found no difference in pregnancy incidence 
by time on ART (29). 
 
One study used time-varying CD4 count and adherence as a proxy for quality of ART use (20). 
This study from Johannesburg, South Africa found that pregnancy incidence increased among 
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women on ART when their CD4 count was above 100 cells/mm3 and with better adherence 
(20). Their finding is consistent with two others that found pregnancy incidence to be 
significantly higher among women who initiated at WHO Stage 1/2 instead of WHO Stage 3/4 
(12, 21). 
 
Temporal trends in fertility among HIV-positive women 
A final approach taken has been to examine trends in the fertility of HIV-positive women over 
time. The clinical cohort study from Kenya and Uganda found that pregnancy incidence was 
higher among HIV-positive women enrolled in clinical care in 2005-2006 relative to those 
enrolled in 2001-2004 (Elul et al 2016). For women enrolled between 2007-2009, however, 
pregnancy incidence was no longer different from the earliest years after adjusting for 
compositional changes including ART use, CD4 count and age (as a linear variable). 
 
The study using clinical cohort data from six West African countries found that overall 
pregnancy incidence of women on ART increased over the time period (1998-2011). After 
adjusting for age, CD4 count, WHO clinical stage and hemoglobin at initiation, women who 
initiated ART between 2009-2011 had 58% (95% CI 35-86) higher pregnancy incidence relative 
to those who initiated prior to 2005 (12).  
 
Finally, the population-based study from four demographic and health surveillance sites found 
that the fertility of HIV-positive women, including those not engaged in care, stayed the same at 
two of the study sites and modestly increased at two other two sites over the pre-ART to post-
ART periods (13). When interpreted against a background of secular declines in fertility, 
however, this stability represents increases in the fertility of HIV-positive women relative to 
HIV-negative women (13).1 
 
                                                        
1 Our summary excludes one study that did not account for compositional differences in their clinic 
population over time (25) 
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Discussion 
This systematic review examined the evidence for how the provision of ART has affected the 
fertility patterns of HIV-positive women and the broader relationship between HIV and fertility 
in sub-Saharan Africa. Currently available evidence suggests that: 1) fertility increases among 
women after they have been on ART for a period of time (approximately one year); 2) fertility of 
women on ART is similar to comparable clinic populations of women not yet on ART when 
adjusted for health (e.g. CD4 count), but 3) remains somewhat lower than HIV-negative women.  
 
However, the current evidence is insufficient to be confident in these conclusions. Fertility of 
HIV-positive women relative to HIV-negative women, appropriately accounting for age and 
ART use, is the gold standard comparison and what is required for robust answers to these 
questions. Unfortunately, only one study identified in the review included a purposefully-selected 
HIV-negative comparison population and data on ART use, and in this study ART utilization 
was self-reported and information about timing of ART initiation was not available (1).  
 
Nonetheless, we can make general observations about the effects of ART on the fertility of HIV-
positive women based on existing evidence. Taken together, the reviewed studies suggest that 
women who access ART in the advanced stages of disease increase their fertility after a period of 
time likely due to improvements in their health and associated changes in sexual behavior and 
fertility desires. As more women access ART, the fertility of HIV-positive women who are not 
yet on ART also increases due to the selective removal (onto ART) of those formerly at more 
advanced stages of infection. These two trends contribute to similar age-specific fertility rates 
among HIV-positive women on- and not yet on ART, although their fertility still remains below 
that of HIV-negative women. Furthermore, the relative stability of age-specific fertility among 
HIV-positive women over time may reflect the counterbalancing effects of increased fertility of 
HIV-positive women due to ART and secular declines in fertility (13).  
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Returning to the principal motivation for this study – an urgent need to inform estimates for 
HIV service provision and the monitoring of HIV prevalence, we make the following tentative 
conclusions. First, HIV-positive pregnant women will comprise a growing proportion of the 
ANC population in the near future due to reductions in the fertility differential between HIV-
positive and HIV-negative women, and the longer survival of HIV infected women. The 
implication is that apparent increases in HIV prevalence among pregnant women may reflect 
changes in the fertility differential, as well as reflecting the underlying population-wide HIV 
trends. Failing to account for narrowing of the fertility rate ratio between HIV-positive and HIV-
negative women could result in over-estimates of population HIV increases derived from 
prevalence among pregnant women. Second, although reductions in the fertility differential will 
increase the need for PMTCT services, more of these women will conceive while on ART, 
reducing the risks of onward transmission to their children. 
 
Notably, the data in the reviewed published papers are concentrated over a period in which ART 
was rapidly expanding (2005-2010) but not as well established as today. Changes in the 
characteristics of women initiating ART and the widening of CD4 guidelines suggest that we 
should be cautious about extrapolating data from 2005-2010 to the current or a future situation. 
Additionally, the recent and rapid adoption of the Option B+ policy, which recommends lifelong 
ART to all HIV-positive pregnant women, as well as the WHO’s now recommended policy of 
universal eligibility for ART (30), will mean that women initiate ART at earlier stages in the 
course of their disease before an advanced infection affects their fecundity. As this trend 
continues, the fertility of HIV positive women on ART may begin to look more like that of HIV 
negative women.  
 
Given these recent and rapid changes in ART policy and availability, there is an urgent need to 
analyse more recent data from the post-2010 period. Fortunately, researchers seem aware of this 
need—7 of the 18 studies in this review were published in 2015 or the first few months of 2016, 
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including the only three population-based studies. In the remaining paragraphs, we offer 
guidance for future research on the impact of ART on the fertility of HIV-positive women. 
 
The studies included in the systematic review came largely from HIV clinics. Given the 
limitations of HIV clinic data, which lack an HIV-negative comparison and are limited to the 
subset of HIV positive women engaged in care, other data sources such as ANC clinics, general 
population cohort studies (e.g. demographic surveillance sites), and retrospective population-
based surveys (e.g. DHS and the new Population-based HIV Impact Assessment surveys 
(PHIA)(31)) are likely to be the most informative in the future. Nonetheless, interpretation of 
currently available data from each of these sources is challenging because reporting of ART 
utilization and the timing of ART initiation relative to pregnancy incidence tend to be less precise 
if self-reported. Precision about this is important considering the high risk of potential 
confounding whence many women are diagnosed and initiate ART because they are pregnant, 
particularly under Option B+, and the unique PMTCT needs of women on- and not on ART in 
the first trimester. In all of these data sources, retrospective reporting may be enhanced by 
inclusion of a specific survey question about whether the women was on ART prior to the first 
ANC visit, in addition to the now standard questions about HIV testing and PMTCT provision 
during the pregnancy.  
 
Among these data sources, ANC clinic data are limited because, while they include data about 
both HIV-positive and HIV-negative women, the denominator for each group is unknown. An 
assumption about the population size and prevalence in the catchment population is required in 
order to calculate relative fertility rates. Moreover, to date, routine ANC clinic reporting has not 
tended to include reporting of whether women were already on ART and age stratification is 
often not reported.  
 
Prospective general population cohorts may be considered the gold standard if they also precisely 
identify the timing of ART relative to pregnancy through prospective linkage to HIV service 
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delivery data. However, these data are only available in a few eastern and southern African 
countries, and tend to be among rural populations. DHSs, PHIAs and similar nationally-
representative surveys with retrospective fertility histories potentially overcome this limitation: 
they include both urban and rural populations and will cover a large number of SSA countries. 
These surveys will increasingly include biomarker measurement of antiretroviral use, but 
inclusion of a specific question about whether ART was initiated prior to pregnancy is essential. 
Estimates from retrospective fertility histories, however, are susceptible to survivorship bias in 
which fertility experiences of recently deceased women are excluded, although survivorship bias 
may be less important in the ART era than earlier when HIV mortality was higher. They are also 
susceptible to the underreporting of early infant mortality, which will disproportionately affect 
HIV-positive women not on ART and could artificially inflate estimates of the effect of ART on 
fertility as declines in early infant mortality could appear as increases in fertility.  
 
The current review focused on actual fertility differentials among women on ART relative to 
comparison populations as a critical first step in understanding how ART use affects fertility. 
Future studies, however, should be sensitive to the relative impact of biological versus behavioral 
differences—volitional and not—in the fertility response to ART across settings as they will 
provide essential inputs for models such as Spectrum (32, 33) that attempt to estimate the future 
direction of HIV and the family planning needs—including safe conception counseling—of 
these women.  
 
Conclusion 
Available evidence indicates that fertility increases after the first year on ART, but women on 
ART still have lower fertility than HIV-negative women of the same age. These conclusions, 
however, are based on limited data largely from the 2005-2010 period during which ART was 
scaled-up. Caution should be exercised generalizing to the current era when guidelines have 
changed, women initiate ART earlier, coverage is higher, and women have been on ART longer. 
 16 
Improving evidence about fertility among women on ART is an urgent priority for planning HIV 
resource needs and understanding HIV epidemic trends.   
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APPENDIX 1-PRISMA Checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
3-4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
4-5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  19 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included 
in the meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
6 
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at 
the study or outcome level), and how this information is to be used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6-8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., 
I2) for each meta-analysis.  
n/a 
 
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
n/a 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
6, Fig.1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Tab.1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  7-11 Tab.1 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally with a forest plot.  
7-11, Tab. 1 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  n/a 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  7-11 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  n/a 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).  
12-13 
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Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
12-13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  12-15 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
17 
 
Source:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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APPENDIX 2: Full search strategy for Medline 
Database(s): Ovid MEDLINE(R) 1946 to May 26, 2016 
 
# Searches 
1 exp ANTI-RETROVIRAL AGENTS/ 
2 ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE/ 
3 (HAART or cART or anti retroviral$ or antiretroviral$).ti,ab. 
4 
ART.ti,ab. not (exp REPRODUCTIVE TECHNIQUES, ASSISTED/ or 
CRYOPRESERVATION/ or (assisted reproduct$ or artificial reproduct$ or 
cryopreserv$ or "state of the art").ti,ab.) 
5 exp HIV INFECTIONS/dt, th [Drug Therapy, Therapy] 
6 HIV SEROPOSITIVITY/dt [Drug Therapy] 
7 
((HIV$ or antiHIV$ or human immuno deficiency virus$ or antihuman immuno 
deficiency virus$ or human immunodeficiency virus$ or antihuman 
immunodeficiency virus$) adj (therap$ or agent? or drug?)).ti,ab. 
8 or/1-7 
9 exp PREGNANCY RATE/ 
10 exp PREGNANCY/sn [Statistics & Numerical Data] 
11 exp FERTILITY/ 
12 INFERTILITY/ 
13 INFERTILITY, FEMALE/ 
14 REPRODUCTIVE HEALTH/ 
15 or/9-14 
16 and/8,15 
17 
exp *ANTI-RETROVIRAL AGENTS/ or *ANTIRETROVIRAL THERAPY, 
HIGHLY ACTIVE/ or exp *HIV INFECTIONS/dt, th or *HIV 
SEROPOSITIVITY/dt [Drug Therapy, Therapy] 
18 (HAART or cART or anti retroviral$ or antiretroviral$).ti. 
19 
ART.ti. not (exp REPRODUCTIVE TECHNIQUES, ASSISTED/ or 
CRYOPRESERVATION/ or (assisted reproduct$ or artificial reproduct$ or 
cryopreserv$ or "state of the art").ti,ab.) 
20 
((HIV$ or antiHIV$ or human immuno deficiency virus$ or antihuman immuno 
deficiency virus$ or human immunodeficiency virus$ or antihuman 
immunodeficiency virus$) adj (therap$ or agent? or drug?)).ti. 
21 or/17-20 
22 
((pregnan$ or birth$ or livebirth$ or stillbirth$) adj2 (risk$ or rate? or incidence? 
or prevalen$)).ti,ab. 
23 
(fertil$ or subfertil$ or infertil$ or birthrate? or reproductive health or 
pregnancies).ti,ab. 
24 or/22-23 
25 and/21,24 
26 or/16,25 
27 LETTER/ 
28 EDITORIAL/ 
29 NEWS/ 
30 exp HISTORICAL ARTICLE/ 
31 ANECDOTES AS TOPIC/ 
32 COMMENT/ 
 22 
33 CASE REPORT/ 
34 (letter or comment*).ti. 
35 or/27-34 
36 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 
37 35 not 36 
38 ANIMALS/ not HUMANS/ 
39 exp ANIMALS, LABORATORY/ 
40 exp ANIMAL EXPERIMENTATION/ 
41 exp MODELS, ANIMAL/ 
42 exp RODENTIA/ 
43 (rat or rats or mouse or mice).ti. 
44 or/37-43 
45 26 not 44 
46 2016????.dc,ed,ep,up,yr. 
47 and/45-46 
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